Innovent Biologics Inc.
IVBXF | OTC
$9.90
-$1.40 (-12.39%)
At close: Oct 30, 2026, 2:35 PM ET
$9.90
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 4:00 PM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q4 2025 Dec 31, 2025 | Q2 2025 Jun 30, 2025 | Q4 2024 Dec 31, 2024 | Q2 2024 Jun 30, 2024 | Q4 2023 Dec 31, 2023 | Q2 2023 Jun 30, 2023 | Q4 2022 Dec 31, 2022 | Q2 2022 Jun 30, 2022 | Q4 2021 Dec 31, 2021 | Q2 2021 Jun 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 1.25B | -20.41M | 834.32M | 297.99M | -392.62M | -888.76M | -139.15M | -1.23B | -950.47M | -1.73B | -1B |
Depreciation & Amortization | n/a | 329.73M | 285.71M | 239.85M | 198.67M | 183.14M | 187.62M | 151.85M | 124.93M | 112.66M | 89.51M |
Stock-Based Compensation | 384.84M | n/a | 342.38M | 258.8M | 297.72M | 347.21M | 226.99M | 208.32M | 261.18M | 262.54M | 239.04M |
Other Working Capital | n/a | 9.26B | -363.19M | 472.91M | -25.21M | 575.82M | -9.05M | -402.53M | 89.08M | 769.8M | 94.67M |
Other Non-Cash Items | -1.64B | 493.01M | -1.18B | 376.92M | -200.28M | 301.1M | -565.43M | -490.97M | 30.87M | -215.95M | 487.97M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | 96.89M | -858.34M | 101.11M | n/a | 822.5M |
Change in Working Capital | n/a | 8.86B | -1.17B | 568.95M | -119.13M | 828.02M | -332.93M | 247.5M | -273.21M | 556.54M | -828.39M |
Operating Cash Flow | n/a | 9.66B | 433.68M | 1.5B | -215.63M | 770.7M | -622.89M | -1.11B | -806.7M | -1.01B | -1.02B |
Capital Expenditures | n/a | -228.17M | -41.42M | -266.15M | -699.51M | -521.48M | -597.9M | -467.91M | -428.99M | -717.31M | -348.32M |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | -16.84B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | 9.97B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | 144.57M | -1 | -611.72M | 145.82M | -1.2B | 1.32B | -1.35B | 808.41M | -1.76B | 131.3M |
Investing Cash Flow | n/a | -7.17B | 418.55M | -611.72M | -553.69M | -1.72B | 725.04M | -1.81B | 379.41M | -2.48B | -217.02M |
Debt Repayment | n/a | -572.7M | n/a | n/a | -330.13M | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | -5.13M | 162.96M | -345.82M | 69.32M | 2.34B | 244.69M | 2.67B | 223.73M | 499.71M | 4.5B |
Financial Cash Flow | n/a | 4.05B | 766.48M | -345.82M | -260.81M | 2.34B | 244.69M | 2.67B | 223.73M | 499.71M | 4.5B |
Net Cash Flow | n/a | 992.63M | 7.89B | -1.71B | -515.87M | 706.71M | 158.05M | -167.94M | -3.68M | -1.55B | 1.01B |
Free Cash Flow | n/a | 9.43B | 392.26M | 1.24B | -915.15M | 249.22M | -1.22B | -1.58B | -1.24B | -1.73B | -1.36B |
Adj. Free Cash Flow | -384.84M | 9.43B | 49.88M | 977.71M | -1.21B | -97.99M | -1.45B | -1.79B | -1.5B | -1.99B | -1.6B |
Maintenance CapEx | n/a | n/a | n/a | n/a | n/a | n/a | -187.11M | -467.91M | -129.04M | -717.31M | n/a |
Growth CapEx | n/a | -228.17M | -41.42M | -266.15M | -699.51M | -521.48M | -410.79M | n/a | -299.95M | n/a | -348.32M |
Owner Earnings | n/a | 9.66B | 433.68M | 1.5B | -215.63M | 770.7M | -810M | -1.58B | -935.74M | -1.73B | -1.02B |
Add to Watchlist
Select watchlists to add or remove IVBXF